Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 19129050)

1.

Waking up the sleepers: HIV latency and reactivation.

Mok HP, Lever A.

J Formos Med Assoc. 2008 Dec;107(12):909-14. doi: 10.1016/S0929-6646(09)60013-9. Review.

PMID:
19129050
2.

From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Shan L, Siliciano RF.

Bioessays. 2013 Jun;35(6):544-52. doi: 10.1002/bies.201200170. Epub 2013 Apr 24. Review.

3.

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Colin L, Van Lint C.

Retrovirology. 2009 Dec 4;6:111. doi: 10.1186/1742-4690-6-111. Review.

4.

Therapeutics for HIV-1 reactivation from latency.

Sgarbanti M, Battistini A.

Curr Opin Virol. 2013 Aug;3(4):394-401. doi: 10.1016/j.coviro.2013.06.001. Epub 2013 Jun 28. Review.

PMID:
23810462
5.

The challenge of finding a cure for HIV infection.

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ.

Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.

PMID:
19265012
6.

Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.

Pérez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, Muñoz-Fernandez MA, Moreno S, Castor TP, Calzado MA, Muñoz E.

Curr HIV Res. 2010 Sep;8(6):418-29.

PMID:
20636281
7.

Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.

Choi BS, Lee HS, Oh YT, Hyun YL, Ro S, Kim SS, Hong KJ.

AIDS. 2010 Feb 20;24(4):609-11. doi: 10.1097/QAD.0b013e328333bfa1.

PMID:
20154582
8.

Molecular mechanisms of HIV-1 proviral latency.

Bisgrove D, Lewinski M, Bushman F, Verdin E.

Expert Rev Anti Infect Ther. 2005 Oct;3(5):805-14. Review.

PMID:
16207172
9.

HIV latency.

Siliciano RF, Greene WC.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096. doi: 10.1101/cshperspect.a007096. Review.

10.

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP.

Lancet. 2013 Jun 15;381(9883):2109-17. doi: 10.1016/S0140-6736(13)60104-X. Epub 2013 Mar 29. Review.

11.

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS.

Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7.

12.

The development of immune-modulating compounds to disrupt HIV latency.

Remoli AL, Marsili G, Battistini A, Sgarbanti M.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):159-72. doi: 10.1016/j.cytogfr.2012.05.003. Epub 2012 Jul 4. Review.

PMID:
22766356
13.

Latency: the hidden HIV-1 challenge.

Marcello A.

Retrovirology. 2006 Jan 16;3:7. Review.

14.

Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1.

Gallastegui E, Marshall B, Vidal D, Sanchez-Duffhues G, Collado JA, Alvarez-Fernández C, Luque N, Terme JM, Gatell JM, Sánchez-Palomino S, Muñoz E, Mestres J, Verdin E, Jordan A.

J Virol. 2012 Apr;86(7):3795-808. doi: 10.1128/JVI.05972-11. Epub 2012 Jan 18.

15.

HIV reservoirs, latency, and reactivation: prospects for eradication.

Dahl V, Josefsson L, Palmer S.

Antiviral Res. 2010 Jan;85(1):286-94. doi: 10.1016/j.antiviral.2009.09.016. Epub 2009 Oct 4. Review.

PMID:
19808057
16.

HIV type-1 latency: targeted induction of proviral reservoirs.

Graci JD, Colacino JM, Peltz SW, Dougherty JP, Gu Z.

Antivir Chem Chemother. 2009;19(5):177-87. Review.

PMID:
19483266
17.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM.

Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.

18.

Can HIV infection be eradicated through use of potent antiviral agents?

Josefsson L, Dahl V, Palmer S.

Curr Opin Infect Dis. 2010 Dec;23(6):628-32. doi: 10.1097/QCO.0b013e32833ff1d0. Review.

PMID:
20847693
19.

HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.

Battistini A, Sgarbanti M.

Viruses. 2014 Apr 14;6(4):1715-58. doi: 10.3390/v6041715. Review.

20.

[Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].

Marcello A, Giacca M.

Pathologica. 2000 Aug;92(4):291-3. Italian. No abstract available.

PMID:
11029891
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk